Catalyst
First CRISPR-based therapy PDUFA sets precedent for gene-editing commercialization timelines.
Date
June 20, 2026
Phase
NDA/BLA
Status
confirmed
Signal score
9.4
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.